Background 

Bladder cancer is one of the most common cancers in the United States, and more than 17,000 people die from the disease each year. Many of these deaths occur when cancer spreads to other parts of the body, a process known as metastasis. Once bladder cancer spreads, survival rates are low, and treatments specifically designed to prevent metastasis remain unavailable. Researchers have identified APOBEC3A (A3A), a protein that can trigger lasting changes in cancer cells by activating SOX2, a gene that promotes cancer cell movement, invasion, and spread. This suggests that even brief A3A activity may contribute to the development of metastatic bladder cancer. 

What the Study Will Address 

This study will investigate whether targeting SOX2 can prevent bladder cancer metastasis. Building on preliminary findings that brief A3A activity permanently activates SOX2 and increases cancer cell invasiveness and metastatic tumor growth in mice, researchers will examine whether eliminating SOX2 using a targeted protein-degradation technology called bioPROTAC can reverse these behaviors and prevent cancer from spreading. 

Why It Matters 

This research could reveal a new approach to preventing bladder cancer metastasis, a major cause of bladder cancer deaths. By determining whether SOX2 can be targeted to reduce cancer cell invasion and spread, the study may provide the scientific foundation for future anti-metastatic therapies and offer hope for patients who currently have limited treatment options.